Search the Newsreel

Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History

This article provides comprehensive financial information for Tango Therapeutics, Inc. (TNGX), including its current stock price, historical data, recent news, and analyst ratings. It details the company's focus on precision oncology and its drug development pipeline. The report also includes performance metrics, earnings trends, …

Return on invested capital % of Cango Inc. Class A – MUN:9C00

This article provides financial information for Cango Inc. Class A (MUN:9C00), specifically focusing on its return on invested capital percentage. The content appears to be an excerpt from a financial data platform, likely TradingView, presenting a quantitative financial metric for the company listed on …

TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides an overview of Tango Therapeutics Inc (TNGX), including its latest stock price, market capitalization, key financial metrics, and upcoming earnings date. It also features recent news headlines related to TNGX and discussions on other trending stocks like SPY, HIMS, and NOW, …

Return on assets % of Cango Inc. Class A – MUN:9C00

The article focuses on the "Return on assets %" for Cango Inc. Class A, traded on the Munich Stock Exchange under the ticker 9C00. It presents a screen from TradingView for the specific financial metric, indicating that the market was closed with no trades …

CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46

CCORF has reiterated its Buy rating for Tango Therapeutics (TNGX.US), maintaining its target price at $46. This reflects a continued positive outlook on the company's stock performance by the firm.

Operating cash flow per share of Cango Inc. Class A – MUN:9C00

This page from TradingView displays financial information, specifically focusing on the operating cash flow per share for Cango Inc. Class A (MUN:9C00). It highlights that the market is closed and no trades have occurred. The content is primarily a listing of navigation and footer …

Tango Therapeutics Inc (TNGX) Institutional Confidence

Tango Therapeutics Inc (TNGX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.32%, a significant quarter-over-quarter increase of 24.30%. Steven Cohen is the largest institutional shareholder, holding 568.45K shares.

AngioDynamics Inc. (ANGO) awards 17,966 RSUs and performance rights

AngioDynamics Inc. (ANGO) has granted its SVP of Quality and Regulatory, Warren Nighan Jr., 17,966 restricted stock units (RSUs) and 17,966 performance rights. The RSUs will vest in four equal annual installments from July 2027 to 2030, while the performance rights are tied to …

Long term debt to total assets ratio of Cango Inc. Class A – MUN:9C00

The article focuses on the "Long term debt to total assets ratio" for Cango Inc. Class A, traded under the MUN:9C00 symbol on the Munich Stock Exchange. It appears to be a financial data page from TradingView, displaying a specific financial ratio for the …

AngioDynamics (ANGO) awards director Michael Tarnoff 11,887 shares

AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026. These shares were awarded as restricted stock units for regular annual director compensation and vested immediately upon grant. Following this transaction, Tarnoff directly holds 95,265 common …

AngioDynamics Inc. (ANGO) awards 11,887 RSUs to board director

AngioDynamics Inc. (ANGO) director Wesley Johnson was granted 11,887 restricted stock units (RSUs) on July 15, 2026, as part of his regular annual compensation for board service. These RSUs vested immediately, increasing his direct holdings to 155,425 common shares. The award was processed at …

AngioDynamics (NASDAQ: ANGO) grants RSUs and performance rights to legal chief

AngioDynamics (NASDAQ: ANGO) has granted 21,288 restricted stock units (RSUs) and 21,288 performance rights to its SVP and Chief Legal Officer, Lawrence T. Weiss. The RSUs will vest in four equal annual installments from 2027 to 2030, while the performance rights are tied to …

AngioDynamics Inc (ANGO) director awarded 11,887 shares in annual grant

AngioDynamics Inc. director Howard W. Donnelly was granted 11,887 shares of common stock on July 15, 2026, as part of his regular annual compensation for board service. These shares, representing restricted stock units, vested immediately, increasing his direct holdings to 178,938 shares. This transaction …

RSU grant lifts AngioDynamics Inc. (ANGO) director to 116,921 shares

AngioDynamics Inc. director Jan Stern Reed was granted 11,887 restricted stock units (RSUs) on July 15, 2026, as regular annual compensation for board service. These RSUs immediately vested, increasing Reed's direct holdings to 116,921 common shares. The transaction, reported at $0.00 per share, was …

AngioDynamics (ANGO) director receives 11,887-share stock award

AngioDynamics Inc. (ANGO) director Karen A. Licitra was granted 11,887 shares of common stock on July 15, 2026, as regular annual compensation for her board service. These restricted stock units immediately vested upon grant, increasing her direct holdings to 102,322 shares. The transaction, reported …

AngioDynamics (ANGO) director granted 11,887 immediately vested RSUs

AngioDynamics Inc. director Auen Eileen O'Shea was granted 11,887 restricted stock units (RSUs) as part of her regular annual compensation. These RSUs, which represent 11,887 shares of common stock, vested immediately, increasing her direct holdings to 116,605 shares. The transaction, filed as a Form …

Another crypto company to sell its Bitcoin stash

As Bitcoin (BTC) has been crashing over the last few months, several cryptocurrency companies have been selling their BTC holdings. Bitdeer Technologies Group (Nasdaq: BTDR), one of the largest Bitcoin mining companies, has fully liquidated its corporate BTC holdings in February. Related: Michael Saylor's …

Top 3 Tech Stocks That Are Preparing To Pump In July

This article identifies three technology stocks—Eastman Kodak (KODK), Cango (CANG), and Tucows (TCX)—that are considered oversold based on their Relative Strength Index (RSI) being below 30. All three companies have experienced significant stock price drops over the past month and are highlighted as potential …

ETFs Investing in AngioDynamics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold AngioDynamics, Inc. (A0B9A5) stocks, providing investors with diversification opportunities. The ETFs include a range of styles such as passive and active, and focus on small-cap, micro-cap, health care, and total market segments. Key financial …

Form 4 AngioDynamics Inc For: 21 July By Investing.com

This article reports on a Form 4 filing for AngioDynamics Inc (ANGO) on July 21st, published on July 22, 2026. The article itself is very brief, mainly serving as a notification of the filing and providing a current stock performance for ANGO. It appears …

AngioDynamics (ANGO) SVP uses 8,228 shares to cover RSU tax obligations

Laura Piccinini, SVP International at AngioDynamics (ANGO), disposed of a total of 8,228 shares of common stock across three transactions on July 16, 17, and 20, 2026. These dispositions were exempt and made to satisfy tax withholding obligations related to the vesting of restricted …

Tax-withholding of 45,711 shares by AngioDynamics (ANGO) CEO disclosed

AngioDynamics (ANGO) CEO James C. Clemmer reported five exempt dispositions of common stock totaling 45,711 shares between July 16-20, 2026. These transactions were for tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs), with per-share prices ranging from $13.51 …

AngioDynamics (ANGO) SVP reports 3,838-share tax withholding event

AngioDynamics Inc. SVP/GM Vascular Access, Chad Thomas Campbell, reported tax-related dispositions of 3,838 shares of common stock. These shares were withheld over three separate dates (July 16, 17, and 20, 2026) to cover tax withholding obligations arising from the vesting of restricted stock units …

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, July 14, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jim ClemmerExecutive Vice President and Chief Financial Officer - Steve Trowbridge TAKEAWAYS Total Net Sales -- $86.6 million in the fourth quarter, …

Cango Inc. (NYSE: CANG) implements 10-for-1 share consolidation and new CUSIP

Cango Inc. (NYSE: CANG) has completed a 10-for-1 share consolidation for its Class A and Class B ordinary shares, effective July 20, 2026. The company's Class A ordinary shares are expected to begin trading on a post-consolidation basis on the New York Stock Exchange …

Cango Inc. Announces Effectiveness of 10-for-1 Share Consolidation

Cango Inc. announced the effectiveness of its 10-for-1 share consolidation for both Class A and Class B ordinary shares as of July 20, 2026, at 5:00 P.M. U.S. Eastern Time. The company's Class A ordinary shares are expected to trade on the NYSE on …

Cango completes 10-for-1 reverse stock split By Investing.com

Cango Inc. (NYSE:CANG) has successfully completed a 10-for-1 reverse stock split of its Class A and Class B ordinary shares, with the change becoming effective on Sunday at 5:00 P.M. Eastern Time. The company's Class A ordinary shares began trading on the New York …

Cango Shares Fall Pre-Bell Following 10-for-1 Consolidation

Cango Inc. shares experienced a decline in pre-market trading following a 10-for-1 share consolidation. The company had previously set July 20th as the date for this 1-for-10 reverse stock split. This news comes amidst other recent announcements from Cango Inc., including their Q1 2026 …

Cango To Carry Out 1-for-10 Reverse Stock Split On July 21st, 2026

Cango Inc. (NYSE: CANG) will execute a 1-for-10 reverse stock split on July 21st, 2026. This action aims to increase the per-share trading price of the company's stock. Shareholders will receive one new share for every ten old shares held, with fractional shares being …

ANGO Q2 2026 Earnings: Narrower Loss Surprises, but Stock Slides 4.46% - Operating Income Trends

AngioDynamics (NASDAQ:ANGO) Rating Lowered to "Strong Sell" at Zacks Research

Sangoma Technologies Q2 2026 Earnings: EPS Misses Estimates by a Wide Margin - Earnings Risk Report

Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating

Mizuho has increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $40, up from the previous $36, while maintaining an Outperform rating. This adjustment suggests a positive outlook on the company's future performance and stock valuation.

TNGX Maintained by Mizuho -- Price Target Raised to $40.00

Mizuho has maintained an "Outperform" rating for Tango Therapeutics (TNGX) and increased its price target to $40.00, reflecting optimism about the company's growth in cancer therapies. Despite the positive analyst sentiment, GuruFocus indicates that TNGX is significantly overvalued, trading at 196.2% above its intrinsic …

Mizuho raises Tango Therapeutics stock price target on combo data

Mizuho has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $40 from $36, maintaining an Outperform rating, based on promising new data for its drug combinations in pancreatic cancer. This comes amidst recent positive analyst revisions and a significant stock offering, with the …

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 6.1% - Time to Buy?